Someone associated with Samumed just e-mailed me the below today and I was pleasantly surprised since I have not contacted the company recently. The e-mail pertains to their SM04554 topical product to treat male pattern hair loss. Please list your questions for Dr. Yusuf Yazici in the comments, but do not be disappointed if he never responds.
Even though they have offered us the opportunity per the last sentence of the below e-mail, I have doubts that I will get any response. Any profanity or sarcasm laced comments will be deleted and/or ignored.
Subject: Samumed presented data on increases in hair follicles observed in its Phase 2 biopsy study for a potential treatment of androgenetic alopecia (AGA) at annual meeting of the American Academy of Dermatology (AAD).
I wanted to share a brief update about Samumed, which presented the results to its phase 2 biopsy study on a potential treatment for androgenetic alopecia at the annual meeting of the American Academy of Dermatology.
Specifically, the study revealed three compelling findings:
- There were statistically significantly higher total follicle counts compared to the vehicle.
- Samumed’s treatment may be the first leading to follicular neogenesis.
- There were no serious adverse events reported.
The full release can be viewed on Samumed’s website and I’ve also copied the text below.
Please let me know if you’d like to speak with Samumed’s Chief Medical Officer, Yusuf Yazici, and I’d be happy to connect you.